医学
采样(信号处理)
宫颈癌
宫颈癌筛查
人乳头瘤病毒
全球卫生
大流行
家庭医学
环境卫生
2019年冠状病毒病(COVID-19)
癌症
护理部
公共卫生
病理
电信
内科学
探测器
传染病(医学专业)
疾病
计算机科学
作者
Beatriz Serrano,Raquel Ibáñez,Claudia Robles,Paula Peremiquel‐Trillas,Sílvia de Sanjosé,Laia Bruni
标识
DOI:10.1016/j.ypmed.2021.106900
摘要
An increasing body of evidence supports the validity of self-sampling as an alternative to clinician collection for primary Human Papillomavirus (HPV) screening. Self-sampling effectively reaches underscreened women and can be a powerful strategy in low- and high-resource settings for all target ages. This work aims to summarize the current use of HPV self-sampling worldwide. It is part of a larger project that describes cervical cancer screening programmes and produces standardized coverage estimates worldwide. A systematic review of the literature and official documents supplemented with a formal World Health Organisation country consultation was conducted. Findings show that the global use of HPV self-sampling is still limited. Only 17 (12%) of countries with identified screening programs recommend its use, nine as the primary collection method, and eight to reach underscreened populations. We identified 10 pilots evaluating the switch to self-sampling in well-established screening programs. The global use of self-sampling is likely to increase in the coming years. COVID-19's pandemic has prompted efforts to accelerate HPV self-sampling introduction globally, and it is now considered a key element in scaling up screening coverage. The information generated by the early experiences can be beneficial for decision-making in both new and existing programs.
科研通智能强力驱动
Strongly Powered by AbleSci AI